Skip to content

The Efficacy and Security of the Small Stitch Technique in Emergency Surgery

Clinical Trial on the Efficacy and Security of the Small Stitch Technique Versus the Large Stitch Closure Laparotomy Technique in Emergency Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03765060
Acronym
STCU
Enrollment
105
Registered
2018-12-05
Start date
2018-10-01
Completion date
2021-12-01
Last updated
2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Wall Defect, Abdominal Wall Hernia, Eventration, Evisceration; Operation Wound

Brief summary

This study evaluates the abdominal closure technique in emergency surgery. Half of participants will be perform the classic Large Stitch technique, while the other half will undergo the Small Stitch technique.

Detailed description

The closure of laparotomy is one of the most important challenges facing the surgeon. The classic technique of wall closure is the Large Stitch technique that uses monofilament double-strand sutures with a SL/WL (Suture Lengh/Wound Lengh) 4:1 ratio, with a distance to the alba line and between each stitch of 1 cm. Nowadays, the Small Stitch technique is accepted as the technique of choice for closure of laparotomies in programmed surgery. It is based on a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR (Half-circle Round body) 26 needle. Stitches should be given with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. There are very few studies about the role of Small Stitch technique in the field of Emergency Surgery where the increased morbidity of the patient and the higher rate of surgical wound infection can play a fundamental role, and could be improved with the use of new abdominal wall closure techniques.

Interventions

PROCEDUREMonomax® 2/0 HR26

It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle. In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.

PROCEDUREMonomax® 1 HR48

It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle. In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.

Sponsors

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients over 18 years of age and who provide informed consent to participate in the study. 2. Patients requiring an urgent midline laparotomy with a minimum size of 8 cm.

Exclusion criteria

1. Prior midline laparotomy. 2. Patients with BMI\> 45 kg / m2 3. Patients with ASA (American Society of Anesthesiologists)\> IV. 4. Patient with an advanced terminal illness with an expectation of life \<1 year. 5. Patients with abdominal aortic aneurysm. 6. Patients with coagulopathy: patient previously diagnosed with von Willebrand disease, hemophilia or Immune thrombocytopenic purpura. 7. Immunosuppressed patient: HIV patients in the AIDS phase, chronic corticosteroid or immunosuppressive treatment. 8. Patients with collagen pathology: patient previously diagnosed with Marfan syndrome, Ehlers-Danlos syndrome, homocystinuria and scleroderma. 9. Chemotherapeutic treatment 2 weeks before surgery. 10. Radiotherapy treatment 6 weeks before surgery. 11. Diffuse peritonitis with hemodynamic instability, defined by non-response to fluids prior to surgery or during the surgical process. 12. Pregnant or potentially fertile women, breastfeeding, or intention to become pregnant, or those who do not wish to use effective contraception (hormonal contraceptives (implantation, patches, oral), and double barrier methods (any double combination of: IUD (intrauterine device), male or female prophylactics with spermicidal gel, diaphragm, contraceptive sponge, cervical cap).

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the small stitch technique defined by eventration rate1 yearTo determine the efficacy of the Small stitch technique versus the Large Stitch technique in the closure of midline laparotomy with respect to the production of eventration in patients undergoing urgent abdominal surgery.

Secondary

MeasureTime frameDescription
Efficacy of the small stitch technique defined by local complications rate1 yearTo determine whether the closure of midline laparotomy with the Small Stitch technique in patients undergoing urgent abdominal surgery reduces the local complications of the surgical wound defined by hematoma, seroma or wound infection.
Efficacy of the small stitch technique defined by evisceration rate1 yearTo determine if the closure of the midline laparotomy with the Small Stitch technique in patients undergoing urgent abdominal surgery reduces the rate of evisceration.
Efficacy of the small stitch technique defined by improvement of quality of life1 yearTo determine if the closure of a midline laparotomy with the Small Stitch technique in patients undergoing urgent abdominal surgery improves the quality of life.
Security of the small stitch technique1 yearTo determine the safety of the Small Stitch technique versus the Large Stitch technique in the closure of the midline laparotomy with respect to the incidence of adverse events and serious adverse events, the incidence of side effects related to the treatment and the incidence and the reasons for premature withdrawal of premature patient from the study.

Countries

Spain

Contacts

Primary ContactTamayo López María Jesús, PhD
mtamayolopez@gmail.com686589986
Backup ContactTallón Aguilar Luis, MD
ltallona@hotmail.com653393951

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026